PEN Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Penumbra Inc (PEN) is not a strong buy for a beginner, long-term investor at this moment. Despite strong financial performance and positive growth trends, the stock faces significant headwinds, including insider selling, neutral hedge fund activity, and a lack of recent positive news or trading signals. Additionally, technical indicators and options data do not suggest a favorable entry point. The pending acquisition by Boston Scientific further complicates the investment outlook.
The stock is trading near its pivot level of 336.527, with resistance at 338.366 and support at 334.687. The MACD is below 0 and negatively contracting, indicating bearish momentum. RSI is neutral at 48.639, and moving averages are converging, suggesting no clear trend.
Strong financial performance in Q4 2025 with YoY revenue growth of 22.14%, net income growth of 40.55%, and EPS growth of 46.34%. Gross margin also improved by 1.84%.
Insider selling has increased by 617.99% over the last month. Hedge funds are neutral, and there are no significant trading trends. Analysts have downgraded the stock due to the pending acquisition by Boston Scientific. The stock has a 60% chance of declining in the short term based on candlestick pattern analysis.
In Q4 2025, Penumbra reported revenue of $385.39M (up 22.14% YoY), net income of $47.34M (up 40.55% YoY), EPS of 1.2 (up 46.34% YoY), and gross margin of 68.02% (up 1.84% YoY).
Analysts have mixed views. Evercore ISI raised the price target to $360 and maintains an Outperform rating, citing strong U.S. Embo growth. However, Truist and Baird downgraded the stock to Hold/Neutral due to the pending acquisition by Boston Scientific, despite increasing price targets to $374.
